Herbs and liver injury: A clinical perspective

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 7, 2014, Pages 1069-1076

  Rossi, Simona ^a   Navarro, Victor J ^a  

^a EINSTEIN MEDICAL CENTER   (United States)

Author keywords

Causality assessment in drug induced liver injury; Dietary supplements induced liver injury; Herbal and induced liver injury

Indexed keywords

ANABOLIC AGENT; CIMICIFUGA RACEMOSA EXTRACT; GLUCOSAMINE; GREEN TEA EXTRACT; HERBACEOUS AGENT; KAVA; PYRROLIZIDINE ALKALOID; USNIC ACID;

ACTAEA RACEMOSA; ARTICLE; CLINICAL FEATURE; DIET SUPPLEMENTATION; ENZYME DEFECT; FOOD CONTAMINATION; HEALTH PROMOTION; HERB; HERBAL AND DIETARY SUPPLEMENT; HERBAL AND DIETARY SUPPLEMENT INDUCED LIVER INJURY; HUMAN; INCIDENCE; LIVER INJURY; LIVER TOXICITY; PIPER METHYSTICUM; SINGAPORE; SPAIN; TEA; UNITED STATES; WEIGHT REDUCTION;

EID: 84902549406     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.07.030     Document Type: Article

References (121)

1. Metcalfe A., Williams J., McChesney J., et al. Use of complementary and alternative medicine by those with a chronic disease and the general population: results of a national population based survey. BMC Complement Altern Med 2010, 10:58.
2. Seeff L.B., Curto T.M., Szabo G., et al. Herbal product use by persons enrolled in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) Trial. Hepatology 2008, 47:605-612.
3. Blendon R.J., DesRoches C.M., Benson J.M., et al. Americans' views on the use and regulation of dietary supplements. Arch Intern Med 2001, 161:805-810.
4. Radimer K., Bindewald B., Hughes J., et al. Dietary supplement use by US adults: data from the National Health and Nutrition Examination Survey, 1999-2000. Am J Epidemiol 2004, 160:339-349.
5. Timbo B.B., Ross M.O.P.P., McCarthy P.V., et al. Dietary supplements in a national survey: prevalence of use and reports of adverse events. JAm Diet Assoc 2006, 106:1966-1974.
6. Cavaliere C., Rea P., Lynch M.E., et al. Herbal supplement sales rise in all channels in 2009. Herbal Gram 2010, 86:62-65.
7. Available at: Accessed February 25,2013. http://www.who.int/mediacentre/factsheets/fs134/en/.htm.
8. Sgro C., Clinard F., Ouazir K., et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002, 36:451-455.
9. De Valle M.B., Av Klinteberg V., Alem N., et al. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther 2006, 24:1187-1195.
10. De Abajo F.J., Montero D., Madurga M., et al. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 2004, 58:71-80.
11. Galan M.V., Potts J.A., Silverman A.L., et al. The burden of acute nonfulminant drug-induced hepatitis in a United States tertiary referral center [corrected]. JClin Gastroenterol 2005, 39:64-67.
12. Vuppalanchi R., Liangpunsakul S., Chalasani N. Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States?. Am J Gastroenterol 2007, 102:558-562.
13. Andrade R.J., Lucena M.I., Fernandez M.C., et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10 year period. Gastroenterology 2005, 129:512-521.
14. Ibanez I., Perez E., Vidal X., et al. Grup d'Estudi Multicentric d'Hepatotoxicitat Aguda de Barcelona (GEM-HAB): prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases; epidemiological and clinical features, and exposure to drugs. JHepatol 2002, 37:592-600.
15. Wai C.T. Presentation of drug-induced liver injury in Singapore. Singapore Med J 2006, 47:116-120.
16. Johannsson M., Ormarsdottir S., Olafsson S. Hepatotoxicity associated with the use of herbalife. Laeknabladid 2010, 96:167-172.
17. Navarro V.J., Barnhart H.X., Bonkovsky H.L., et al. Herbal and dietary supplement induced hepatotoxicity in the U.S. Gastroenterology 2012, 142. S1, S-41.
18. U.S. Food and Drug Administration. Dietary supplements. Available at: Accessed February 25,2013. http://www.fda.gov/Food/DietarySupplements/default.htm.
19. U.S. Food & Drug Administration. Dietary supplements guidance documents & regulatory information. Available at: Accessed February 25,2013. http://www.fda.gov/food/guidanceregulation/guidancedocumentsregulatoryinformation/dietarysupplements/default.htm.
20. Department of Health and Human Services. Manufacturer ofdietary supplements. Available at: Accessed February 25,2013. http://www.crnusa.org/FDAunity/FDAManufacturerDietarySupplements121510.pdf.
21. Fontana R.J., Seeff L.B., Andrade R.J., et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology 2010, 52:730-742.
22. Teschke R., Schwarzenboeck A., Eickhoff A., et al. Clinical and causality assessment in herbal hepatotoxicity. Expert Opin Drug Saf 2013, 12:339-366.
23. Danan G., Benichou C. Causality assessment of adverse reactions to drugs-I: a novel method based on the conclusions of international consensus meetings; application to drug-induced liver injuries. JClin Epidemiol 1993, 46:1323-1330.
24. Arimone Y., Begaud B., Miremont-Salame G., et al. Agreement of expert judgment in causality assessment of adverse drug reactions. Eur J Clin Pharmacol 2005, 61:169-173.
25. Naranjo C.A., Busto U., Sellers E.M., et al. Amethod for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981, 30:239-245.
26. Sarma D.N., Barrett M.L., Chavez M.L., et al. Safety of green tea extracts: a systematic review by the US Pharmacopeia. Drug Saf 2008, 6:469-484.
27. Teschke R., Schmidt-Taenzer W., Wolff A. Spontaneous reports of assumed herbal hepatotoxicity by black cohosh: is the liver-unspecific Naranjo scale precise enough to ascertain causality?. Pharmacoepidemiol Drug Saf 2011, 20:567-582.
28. Teschke R., Schulze J. Suspected herbal hepatotoxicity: requirements for appropriate causality assessment by the US Pharmacopeia. Drug Saf 2012, 35:1091-1097.
29. Benichou C., Danan G., Flahault A. Causality assessment of adverse reactions to drugs-II: an original model for validation of drug causality assessment methods-case reports with positive rechallenge. JClin Epidemiol 1993, 46:1331-1336.
30. Maria V.A., Victorino R.M. Development and validation of a clinical scale for the diagnosis of drug induced hepatitis. Hepatology 1997, 26:664-669.
31. Fontana R.J., Watkins P.B., Bonkovsky H.L., et al. Rationale, design and conduct of the Drug Induced Liver Injury Network prospective study. Drug Saf 2009, 32:55-68.
32. Rockey D.C., Seeff L.B., Rochon J., et al. US Drug-Induced Liver Injury Network: causality assessment in drug-induced liver injury using a structured expert opinion process-comparison to the Roussel-Uclaf causality assessment method. Hepatology 2010, 51:2117-2126.
33. Chalasani N., Fontana R.J., Bonkovsky H.L., et al. Causes, clinical features, and outcomes from a prospective study of drug induced liver injury in the United States. Gastroenterology 2008, 135:1924-1934.
34. Navarro V.J., Barnhart H.X., Bonkovsky H.L., et al. Diagnosing hepatotoxicity attributable to herbal & dietary supplements (HDS): test-retest reliability of a novel causality assessment tool. JHepatol 2012, 56:S536.
35. Harkey M.R., Henderson G.L., Gershwin M.E., et al. Variability in commercial Ginseng products: an analysis of 25 preparations. Am J Clin Nutr 2002, 75:600-601.
36. Zhang H., Yu C., Jia J.Y., et al. Contents of four active components in different commercial crude drugs and preparations of danshen (Salvia miltiorrhiza). Acta Pharmacol Sin 2002, 23:1163-1168.
37. Manning J., Roberts J.C. Analysis of catechin content of commercial green tea products. JHerb Pharmacother 2003, 3:19-32.
38. Garrara J., Hamrs S., Eberly L.E., et al. Variations in product choices of frequently purchased herbs: caveat emptor. Arch Intern Med 2003, 163:2290-2295.
39. Stevens T., Qadri A., Zein N.N. Two patients with acute liver injury associated with use of the herbal weight-loss supplement hydroxycut. Ann Intern Med 2005, 1426:477-478.
40. Available at: Accessed April 2,2013. http://fda.gov/NewsEvents/Newsroom/PressAnnouncements/2004/ucm108379.htm.
41. Jones F.J., Andrews A.H. Acute liver injury associated with the herbal supplement Hydroxycut in a soldier deployed to Iraq. Am J Gastroenterol 2007, 102:2357-2358.
42. Shim M., Saab S. Severe hepatotoxicity due to hydroxycut: a case report. Dig Dis Sci 2009, 54. 406-08.
43. Dara L., Hewett J., Kim J.K. Hydroxycut hepatotoxicity: a case series and review of the liver toxicity from herbal weight loss supplements. World J Gastroenterol 2008, 14:6999-7004.
44. Fong T.L., Klontz K.C., Canas-Coto A., et al. Hepatotoxicity due to hydroxycut: a case series. Am J Gastroenterol 2010, 105:1561-1566.
45. Available at: Accessed February 25,2013. http://www.fda.gov/oc/opacom/hottopics/hydroxycut/consumeradvisory.html.
46. Herbalife. Available at: Accessed February 25,2013. http://www.herbalife.com.
47. Elinav E., Pinsker G., Safadi R., et al. Association between consumption of herbalife nutritional supplements and acute hepatotoxicity. JHepatol 2007, 47:514-520.
48. Schoepfer A.M., Engel A., Fattinger K., et al. Herbal does not mean innocuous: ten cases of severe hepatotoxicity associated with dietary supplements from Herbalife products. JHepatol 2007, 47:521-526.
49. Manso G., Lopez-Rivas L., Salgueiro M.E., et al. Continuous reporting of new cases in Spain supports the relationship between Herbalife products and liver injury. Pharmacoepidemiol Drug Saf 2011, 20:1080-1087.
50. Jimenez-Lopez J.M., Cederbaum A.I. Green tea polyphenol epigallocatechin-3-gallate protects HepG2 cells against CYP2E1-dependent toxicity. Free Radic Biol Med 2004, 36:359-370.
51. Zhong Z., Froh M., Connor H.D., et al. Prevention of hepatic ischemia: reperfusion injury by green tea extract. Am J Physiol Gastrointest Liver Physiol 2002, 283:957-964.
52. Zhong Z., Froh M., Lehnert M., et al. Polyphenols from Camellia sinensis attenuate experimental cholestasis-induced liver fibrosis in rats. Am J Physiol Gastrointest Liver Physiol 2003, 285:1004-1013.
53. Garcia-Moran S., Saez-Royuela F., Cento E. Acute hepatitis associated with Camellia thea and Orthosiphon ingestion. Gastroenterol Hepatol 2004, 27:559-560.
54. Gloro R., Hourmand-Ollivier I., Mosquet B., et al. Fulminant hepatitis during self-medication with hydroalchoholic extract of green tea. Eur J Gastroenterol Hep 2005, 17:1135-1137.
55. Jimenez-Saenz M., Martinez-Sanchez M. Acute hepatitis associated with the use of green tea infusions. JHepatol 2006, 44:616-617.
56. Molinari M., Watt K.D., Kruszyna T., et al. Acute liver failure induced by green tea extracts: a case report and review of the literature. Liver Transpl 2006, 12:1892-1895.
57. Available at: Accessed March 24,2013. http://apps.who.int/medicinedocs/en/d/Js4946e/1.4html.
58. Isbruker R.A., Edwards J.A., Wolz E., et al. Safety studies on epigallocatechin gallate (EGCG) preparations: part 2-dermal, acute and short term toxicity studies. Food Chem Toxicol 2006, 44:636-650.
59. Chow H.H., Hakim I.A., Vining D.R., et al. Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals. Clin Cancer Res 2005, 11:627-633.
60. Garcia-Cortes M., Borraz Y., Lucena M.I., et al. Liver injury induced by "natural remedies": an analysis of cases submitted to the Spanish Liver Toxicity Registry. Rev Esp Enferm Dig 2008, 11:688-695.
61. USP. Update on the USP green tea extract monograph. Available at: Accessed March 26,2013. http://www.usp.org/usp-nf/notices/retired-compendial-notices/update-usp-green-tea-extract-monograph.
62. Sarma D.N., Barrett M.L., Chavez M.L., et al. Safety of green tea extracts: a systematic review by the US Pharmacopeia. Drug Saf 2008, 31:469-484.
63. Guo L., Qiang S., Fang J.L., et al. Review of usnic acid and Usnea Barbata toxicity. JEnviron Sc Health C Environ Carcinoq Ecotoxicol Rev 2008, 26:317-338.
64. Cutting W.C., Mehrtens H.G., Tainter M.L. Actions and uses of dinitriophenol: promising metabolic applications. JAMA 1933, 15:193-195.
65. Colman E. Dinitrophenol and obesity: an early twentieth-century regulatory dilemma. Regul Toxicol Pharmacol 2007, 48:115-117.
66. Miranda E.J., McIntyre I.M., Parker D.R., et al. Two deaths attributed to the use of 2,4-dinitrophenol. JAnal Toxicol 2006, 30:219-222.
67. Favreau J.T., Ryu M.L., Braunstein G., et al. Severe hepatotoxicity associated with the dietary supplement LipoKinetrix. Ann Intern Med 2002, 136:590-595.
68. Durazo F.A., Lassman C., Han S.B., et al. Fulminant liver failure due to usnic acid for weight loss. Am J Gastroenterol 2004, 99:950.
69. Neff G.W., Reddy R.K., Durazo F.A., et al. Severe hepatotoxicity associated with the use of weight loss diet supplements containing ma huang or usnic acid. JHepatol 2004, 41:1061-1067.
70. Sanchez W., Maple J.T., Burgart L.J., et al. Severe hepatotoxicity associated with the use of a dietary supplement containing usnic acid. Mayo Clin Proc 2006, 81:541-544.
71. U.S. Food and Drug Administration. Reporting serious problems to FDA. Available at: Accessed March 23,2013. http://www.fda.gov/medwatch/how.htm.
72. Liske E. Therapeutic efficacy and safety of Cimicifuga racemosa for gynecologic disorders. Adv Ther 1998, 15:45-53.
73. Vitetta L., Thomsen M., Sali A. Black cohosh and other herbal remedies associated with acute hepatitis A. Med J Aust 2003, 21:411-412.
74. Nisbet B.C., O'Connor R.E. Black cohosh-induced hepatitis. Del Med J 2007, 79:441-444.
75. Lontos S., Jones R.M., Angus P.W., et al. Acute liver failure associated with the use of herbal preparations containing black cohosh. Med J Aust 2003, 179:390-391.
76. Whiting P.W., Clouston A., Kerlin P. Black cohosh and other herbal remedies associated with acute hepatitis. Med J Aust 2002, 21:440-443.
77. Levitsky J., Alli T.A., Wisecarver J., et al. Fulminant liver failure associated with the use of black cohosh. Dig Dis Sci 2005, 50:538-539.
78. Lynch C.R., Folkers M.E., Hutson W.R. Fulminant hepatic failure associated with the use of black cohosh: a case report. Liver Transpl 2006, 12:989-992.
79. Joy D., Joy J., Duane P. Black cohosh: a cause of abnormal postmenopausal liver function tests. Climacteric 2008, 11:84-88.
80. Vannacci A., Lapi F., Gallo E., et al. Acase of hepatitis associated with long-term use of Cimicifuga racemosa. Altern Ther Health Med 2009, 15:62-63.
81. Mahady G.B., Low Dog T., Barrett M.L., et al. United States pharmacopeia of the black cohosh case reports of hepatotoxicity. Menopause 2008, 15:628-638.
82. Teschke R., Schwarzenboweck A. Suspected hepatotoxicity by Cimiscifuga racemosa rhizoma (black cohash root): critical analysis and structures causality assessment. Phytomedicine 2009, 16:72-84.
83. Teschke R. Black cohosh and suspected hepatotoxicity: inconsistencies, confounding variables, and prospective use of a diagnostic causalty algorithm-a critical review. Menopause 2010, 17:426-440.
84. Smith L.W., Culvenor C.C.J. Plant sources of hepatotoxic pyrrolizidine alkaloids. JNat Prod 1981, 44:129-152.
85. Mohabbat O., Srivastava R.N., Younos M.S., et al. An outbreak of hepatic veno-occlusive disease in North-Western Afghanistan. Lancet 1976, 2:271-276.
86. Tandon B.N., Tandon R.K., Tandon H.D., et al. An epidemic of veno-occlusive disease in Central India. Lancet 1976, 2:271-272.
87. Weston C.F.M., Cooper B.Y., Davies J.E., et al. Veno-occlusive disease of the liver secondary to ingestion of comfrey. Br Med J 1987, 295:183.
88. Bras G., Jeliffe D.B., Stuart K.L. Veno-occlusive disease of the liver with non-portal type of cirrhosis occurring in Jamaica. AMA Arch Pathol 1954, 57:285-300.
89. Stillman A.E., Huxtable R.J., Consroe P., et al. Hepatic veno-occlusive disease due to pyrrolizidine (Senecio) poisoning in Arizona. Gastroenterology 1977, 73:349-352.
90. Huan J.Y., Miranda D.R., Buhler P.R., et al. Species differenced in the hepatic microsomal enzyme metabolism of the pyrrolizidine alkaloids. Toxicol Lett 1998, 99:127-137.
91. Prakash A.S., Pereira T.N., Reilly P., et al. Pyrrolizidine alkaloids in human diet. Mutat Res 1999, 443:53-67.
92. Chojkier M. Hepatic sinusoidal-obstruction syndrome: toxicity of pyrrolizidine alkaloids. JHepatol 2003, 3:437-446.
93. Singh Y.N. Kava: an overview. JEthnopharmoacol 1992, 37:13-45.
94. Strahl S., Ehret V., Dahm H.H., et al. Necrotizing hepatitis after taking herbal medication. Dtsch Med Wschr 1998, 123:1410-1414.
95. Eschar M., Sesmeules J. Hepatitis associated with Kava, an herbal remedy for anxiety. BMJ 2001, 322:139.
96. Bujanda L., Palacios A., Silvarino R., et al. Kava-induced acute icteric hepatitis. Gastroenterol Hepatol 2002, 6:434-435.
97. Stickel F., Baumuller H.M., Seitz K., et al. Hepatitis induced by Kava (Piper methysticum rhizorna). JHepatol 2003, 39:62-67.
98. Kraft M., Spahn T.W., Menzel J., et al. Fulminant liver failure after administration of the herbal antidepressant Kava-Kava. Dtsch Med Wochenschr 2001, 126:970-972.
99. Thomsen M., Vitetta L., Schmidt M., et al. Fatal fulminant hepatic failure induced by a natural therapy containing kava. Med J Aust 2004, 180:198-199.
100. Ulbricht C., Basch E., Boon H., et al. Safety review of kava (Piper methysticum) by the Natural Standard Research Collaboration. Expert Opin Drug Saf 2005, 4:779-794.
101. Teschke R., Schwarzenboeck A., Hennermann K.H. Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases. Eur J Gastroenterol Hepatol 2008, 20:1182-1193.
102. Teschke R., Wolff A. Kava hepatotoxicity: regulatory data selection and causality assessment. Dig Liver Dis 2009, 41:891-901.
103. Guidance for industry: frequently asked questions about medical foods 2007, U.S. Food and Drug Administration, U.S. Department of Health and Human Services, Silver Spring, MD, Available at:, Accessed January 2, 2012. http://www.fda.gov/food/guidanceregulation/guidancedocumentsregulatoryinformation/medicalfoods/ucm054048.htm.
104. Altavilla D., Squadrito F., Bitto A., et al. Flavocoxid, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, blunts pro-inflammatory phenotype activation in endotoxin-stimulated macrophages. BrJ Pharmacol 2009, 157:1410-1418.
105. Chalasani N., Vuppalanchi R., Navarro V.J., et al. Acute liver injury due to Flavocoxid (limbrel), a medical food for osteoarthritis: a case series. Ann Intern Med 2013, 156:857-860.
106. Morgan S.L., Baggott J.E., Moreland L., et al. The safety of flavocoxid, a medical food, in the dietary management of knee osteoarthritis. JMed Food 2009, 12:1143-1148.
107. Levy R.M., Khokhlov A., Kopenkin S., et al. Efficacy and safety of flavocoxid, a novel therapeutic, compared with naproxen: a randomized multicenter controlled trial in subjects with osteoarthritis of the knee. Adv Ther 2010, 27:731-742.
108. Pillai L., Burnett B.P., Levy R.M., et al. GOAL: multicenter, open-label, post-marketing study of flavocoxid, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin. Curr Med Res Opin 2010, 26:1055-1063.
109. Primus Pharmaceuticals. Limbrel product information 2011, Primus Pharmaceuticals, Scottsdale, AZ, Available at:, Accessed February 25, 2013. http://www.limbrel.com/downloads/limbrel_pi.
110. Linnebur S.A., Rapacchietta O.C., Vejar M., et al. Hepatotoxicity associated with Chinese skullcap contained in Move Free Advanced dietary supplement: two case reports and review of the literature. Pharmacotherapy 2010, 30(750):258e-262e.
111. Ebrahim V., Albeldawi M., Chiang D.J. Acute liver injury associated with glucosamine dietary supplement. BMJ Case Rep 2012, 10.1136/bcr-2012-007665.
112. US Department of Justice, Drug Enforcement Administration (DEA). Rules 2005: implementation of the Anabolic Steroid Control Act of 2004. Available at: Accessed February 25,2013. http://www.deadiversion.usdoj.gov/fed_regs/rules/2005/fr1216/htm.
113. Ishak K.G. Hepatic lesions caused by anabolic and contraceptive steroids. Semin Liver Dis 1981, 1:116-128.
114. Haupt H.A., Rovere G.D. Anabolic steroids: a review of the literature. Am J Sports Med 1984, 12:469-484.
115. Boada L.D., Zumbado M., Torres S., et al. Evaluation of acute and chronic hepatotoxic effects exerted by anabolic-androgenic steroid stanozolol in adult male rats. Arch Toxicol 1999, 73:465-472.
116. Marin N.M., Dayyeh B.K., Chung R.T. Anabolic steroid abuse causing recurrent hepatic adenomas and hemorrhage. World J Gastroenterol 2008, 14:4573-4575.
117. Elsharkawy A.M., McPherson S., Masson S., et al. Cholestasis secondary to anabolic steroid use in young men. BMJ 2012, 34. 4e468.
118. Turani H., Levi J., Levin D., et al. Hepatic lesions in patients on anabolic therapy. Isr J Med Sci 1983, 19:332-337.
119. Timchec-Hariri A., Balali-Mood M., Aryan E., et al. Toxic hepatitis in a group of 20 male body-builders taking dietary supplements. Food Chem Toxicol 2012, 50:3826-3832.
120. Singh V., Rudraraju M., Carey E., et al. Severe hepatotoxicity caused by a Methasteron-containing performance-enhancing supplement. JClin Gastroenterol 2009, 43:287.
121. DesJardins M. Supplement use in the adolescent athlete. Curr Sports Med Rep 2002, 1:369-373.